Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients.
Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research.
Localized radiation therapy against a tumor can trigger a beneficial immune response throughout the body by releasing DNA from mitochondria into the cytoplasm of tumor cells, according to new preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.
Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
A prestigious Cancer Moonshot grant from the National Cancer Institute’s Immuno-Oncology Translational Network will enable investigators to explore the mechanisms that allow slow-growing lung cancer lesions to progress into aggressive malignancies and identify new therapeutic strategies to intercept the transition.